Masitinib for the treatment of mild to moderate Alzheimer’s disease

Alzheimer's disease: the amyloid cascade hypothesis

Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · see citing works

Pathways towards and Away from Alzheimer’s Disease

Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052 · see citing works

Amyloid deposition as the central event in the aetiology of Alzheimer’s disease

Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · see citing works

Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models

Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821 · see citing works

Alzheimer’s disease: Clinical trials and drug development

Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217 · see citing works

Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease

in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196 · see citing works

Microglial priming in neurodegenerative disease

Perry, V. H., & Holmes, C. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.38 · Cited by 1,127 · see citing works

Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity

Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H., & Peterson, J. R. (2011) · Nature Biotechnology · doi:10.1038/nbt.2017 · Cited by 919 · see citing works

Stem Cell Factor Receptor/c-Kit: From Basic Science to Clinical Implications

Lennartsson, J., & Rönnstrand, L. (2012) · Physiological Reviews · doi:10.1152/physrev.00046.2011 · Cited by 829 · see citing works

TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants – past, present and future

Sedger, L. M., & McDermott, M. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.016 · Cited by 774 · see citing works

Therapeutics of Alzheimer's disease: Past, present and future

Anand, R., Gill, K. D., & Mahdi, A. A. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 748 · see citing works

Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons

Um, J. W., Nygaard, H. B., Heiss, J. K., Kostylev, M. A., Stagi, M., Vortmeyer, A. O., Wısnıewskı, T., Gunther, E. C., & Strittmatter, S. M. (2012) · Nature Neuroscience · doi:10.1038/nn.3178 · Cited by 654 · see citing works

Clinical trials and late‐stage drug development for <scp>A</scp>lzheimer's disease: an appraisal from 1984 to 2014

Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651 · see citing works

Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer Aβ Oligomer Bound to Cellular Prion Protein

Um, J. W., Kaufman, A. C., Kostylev, M., Heiss, J. K., Stagi, M., Takahashi, H., Kerrisk, M. E., Vortmeyer, A., Wisniewski, T., Koleske, A. J., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.06.036 · Cited by 572 · see citing works

100 Years and Counting: Prospects for Defeating Alzheimer's Disease

Roberson, E. D., & Mucke, L. (2006) · Science · doi:10.1126/science.1132813 · Cited by 550 · see citing works

Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies

Etminan, M., Gill, S., & Samii, A. (2003) · BMJ · doi:10.1136/bmj.327.7407.128 · Cited by 511 · see citing works

NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies

McGeer, P. L., & McGeer, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.013 · Cited by 498 · see citing works

How does diabetes accelerate Alzheimer disease pathology?

Sims-Robinson, C., Kim, B., Rosko, A., & Feldman, E. L. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.130 · Cited by 492 · see citing works

The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy

McGeer, P. L., & McGeer, E. G. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1177-7 · Cited by 467 · see citing works

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

Dubreuil, P., Letard, S., Ciufolini, M., Gros, L., Humbert, M., Castéran, N., Borge, L., Hajem, B., Lermet, A., Sippl, W., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007258 · Cited by 421 · see citing works

Phosphorylation of Tau by Fyn: Implications for Alzheimer's Disease

Lee, G. S., Thangavel, R., Sharma, V. M., Litersky, J. M., Bhaskar, K., Fang, S. M., Lana, H., Andreadis, A., Hoesen, G. W. V., & Ksiȩżak-Reding, H. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.4162-03.2004 · Cited by 414 · see citing works

Structural Basis for Activation of the Receptor Tyrosine Kinase KIT by Stem Cell Factor

Yuzawa, S., Opatowsky, Y., Zhang, Z., Mandiyan, V., Lax, I., & Schlessinger, J. (2007) · Cell · doi:10.1016/j.cell.2007.05.055 · Cited by 359 · see citing works

Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease

Ferreira, S. T., Clarke, J. R., Bomfim, T. R., & Felice, F. G. D. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.12.010 · Cited by 354 · see citing works

Structure and regulation of Kit protein-tyrosine kinase—The stem cell factor receptor

Roskoski, R. J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.150 · Cited by 345 · see citing works

Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer’s disease

Chin, J., Palop, J. J., Puoliväli, J., Massaro, C., Bien-Ly, N., Gerstein, H., Scearce-Levie, K., Masliah, E., & Mucke, L. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2980-05.2005 · Cited by 312 · see citing works

Signaling by Kit protein-tyrosine kinase—The stem cell factor receptor

Roskoski, R. J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.055 · Cited by 280 · see citing works

Structure of a c-Kit Product Complex Reveals the Basis for Kinase Transactivation

Mol, C. D., Lim, K. B., Sridhar, V., Zou, H., Chien, E. Y. T., Sang, B., Nowakowski, J., Kassel, D. B., Cronin, C. N., & McRee, D. E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300186200 · Cited by 273 · see citing works

IL-33/ST2 axis in inflammation and immunopathology

Milovanović, M., Volarević, V., Radosavljevic, G. D., Jovanović, I., Pejnovic, N. N., Arsenijević, N., & Lukić, M. L. (2012) · Immunologic Research · doi:10.1007/s12026-012-8283-9 · Cited by 256 · see citing works

Microglia and mast cells: two tracks on the road to neuroinflammation

Skaper, S. D., Giusti, P., & Facci, L. (2012) · The FASEB Journal · doi:10.1096/fj.11-197194 · Cited by 235 · see citing works

Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors

Tayeb, H. O., Yang, H. D., Price, B. H., & Tarazi, F. I. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.12.002 · Cited by 231 · see citing works

Mast Cells Migrate from Blood to Brain

Silverman, A.-J., Sutherland, A. K., Wilhelm, M., & Silver, R. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-01-00401.2000 · Cited by 228 · see citing works

Screening of innate immune receptors in neurodegenerative diseases: A similar pattern

Letiembre, M., Liu, Y., Walter, S., Hao, W., Pfander, T., Wrede, A., Schulz-Schaeffer, W., & Fassbender, K. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.08.018 · Cited by 228 · see citing works

Rapid Tyrosine Phosphorylation of Neuronal Proteins Including Tau and Focal Adhesion Kinase in Response to Amyloid-β Peptide Exposure: Involvement of Src Family Protein Kinases

Williamson, R., Scales, T., Clark, B. R., Gibb, G., Reynolds, C. H., Kellie, S., Bird, I. N., Varndell, I. M., Sheppard, P. W., Everall, I., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-01-00010.2002 · Cited by 227 · see citing works

Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond?

Mullane, K., & Williams, M. J. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 212 · see citing works

The cholinergic hypothesis of cognitive aging revisited again: Cholinergic functional compensation

Dumas, J. A., & NEWHOUSE, P. A. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.02.022 · Cited by 209 · see citing works

Mitochondria and Cell Bioenergetics: Increasingly Recognized Components and a Possible Etiologic Cause of Alzheimer's Disease

Swerdlow, R. H. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4149 · Cited by 203 · see citing works

Amyloid β, Glutamate, Excitotoxicity in Alzheimer's Disease: Are We on the Right Track?

Esposito, Z., Belli, L., Toniolo, S., Sancesario, G., Bianconi, C., & Martorana, A. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12095 · Cited by 198 · see citing works

The role of inflammasome in Alzheimer's disease

Liu, L., & Chan, C. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2013.12.007 · Cited by 192 · see citing works

Targeting microglia for the treatment of Alzheimer’s Disease

Wes, P. D., Sayed, F. A., Bard, F., & Gan, L. (2016) · Glia · doi:10.1002/glia.22988 · Cited by 185 · see citing works

Advances in kinase targeting: current clinical use and clinical trials

Rask‐Andersen, M., Zhang, J., Fabbro, D., & Schiöth, H. B. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.09.007 · Cited by 181 · see citing works

Mast cells on the mind: new insights and opportunities

Silver, R., & Curley, J. P. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2013.06.001 · Cited by 178 · see citing works

Pathways to Alzheimer's disease

Hardy, J., Bogdanović, N., Winblad, B. G., Portelius, E., Andreasen, N. C., Cedazo-Mı́nguez, Á., & Zetterberg, H. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12192 · Cited by 177 · see citing works

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial

Piette, F., Belmin, J., Vincent, H., Schmidt, N., Pariel, S., Verny, M., Marquis, C., Mely, J., Hugonot-Diener, L., Kinet, J., et al. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt75 · Cited by 176 · see citing works

Amyloid-β signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease

Seward, M. E., Swanson, E., Norambuena, A., Reimann, A., Cochran, J. N., Li, R., Roberson, E. D., & Bloom, G. S. (2013) · Journal of Cell Science · doi:10.1242/jcs.1125880 · Cited by 170 · see citing works

Fyn Kinase Modulates Synaptotoxicity, But Not Aberrant Sprouting, in Human Amyloid Precursor Protein Transgenic Mice

Chin, J., Palop, J. J., Yu, G.-Q., Kojima, N., Masliah, E., & Mucke, L. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.0277-04.2004 · Cited by 161 · see citing works

Therapeutic targeting of c-KIT in cancer

Ashman, L. K., & Griffith, R. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.740010 · Cited by 147 · see citing works

Role of Cell Cycle Re-Entry in Neurons: A Common Apoptotic Mechanism of Neuronal Cell Death

Folch, J., Junyent, F., Verdaguer, E., Auladell, C., Pizarro, J. G., Beas‐Zárate, C., Pallàs, M., & Camins, A. (2011) · Neurotoxicity Research · doi:10.1007/s12640-011-9277-4 · Cited by 139 · see citing works

Tr‐kit‐induced resumption of the cell cycle in mouse eggs requires activation of a Src‐like kinase

Sette, C., Paronetto, M. P., Barchi, M., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf553 · Cited by 137 · see citing works

The protein tyrosine kinase, fyn, in Alzheimerʼs disease pathology

Shirazi, S. K., & Wood, J. G. (1993) · Neuroreport · doi:10.1097/00001756-199304000-00024 · Cited by 136 · see citing works

Masitinib, a c‐kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid‐dependent asthmatics

Humbert, M. J. C., Blay, F. D., Garcia, G., et al. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02122.x · Cited by 135 · see citing works

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study

Vermersch, P., Benrabah, R., Schmidt, N., Zéphir, H., Clavelou, P., Vongsouthi, C., Dubreuil, P. C., Moussy, A., & Hermine, O. (2012) · BMC Neurology · doi:10.1186/1471-2377-12-36 · Cited by 134 · see citing works

Targeting TNF: a therapeutic strategy for Alzheimer's disease

Cheng, X., Shen, Y., & Li, R. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.06.029 · Cited by 128 · see citing works

Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST)

Cesne, A. L., Blay, J., Bui, B., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.014 · Cited by 127 · see citing works

Overview and Management of Cardiac Adverse Events Associated With Tyrosine Kinase Inhibitors

Lenihan, D. J., & Kowey, P. R. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0466 · Cited by 122 · see citing works

Migration of mast cells in the developing rat brain

Lambracht-Hall, M., Dimitriadou, V., & Theoharides, T. C. (1990) · Developmental Brain Research · doi:10.1016/0165-3806(90)90077-c · Cited by 121 · see citing works

The case for soluble Aβ oligomers as a drug target in Alzheimer's disease

Hefti, F. F., Goure, W. F., Jerecı̀ć, J., Iverson, K. S., Walicke, P. A., & Krafft, G. A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.03.002 · Cited by 119 · see citing works

Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer’s disease

Manocha, G. D., & Combs, C. K. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-117 · Cited by 119 · see citing works

Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a study

Paul, C. F., Sans, B., Suárez, F., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21894 · Cited by 114 · see citing works

The dendritic hypothesis for Alzheimer's disease pathophysiology

Cochran, J. N., Hall, A. M., & Roberson, E. D. (2014) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2013.12.004 · Cited by 114 · see citing works

New insights into the role of mast cells in autoimmunity: Evidence for a common mechanism of action?

Walker, M. E., Hatfield, J. K., & Brown, M. A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.02.009 · Cited by 113 · see citing works

A critical analysis of the ‘amyloid cascade hypothesis’

A. Armstrong, R. (2014) · Folia Neuropathologica · doi:10.5114/fn.2014.45562 · Cited by 110 · see citing works

Pathogenesis and Disease-modifying Therapy in Alzheimer's Disease: The Flat Line of Progress

Castellani, R. J., & Perry, G. L. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.09.009 · Cited by 103 · see citing works

Mast cells and inflammation

Frenzel, L., & Hermine, O. (2012) · Joint Bone Spine · doi:10.1016/j.jbspin.2012.08.013 · Cited by 101 · see citing works

Masitinib (AB1010), from canine tumor model to human clinical development: Where we are?

Marech, I., Patruno, R., Zizzo, N., et al. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.12.011 · Cited by 88 · see citing works

Targeting microglia for the treatment of Alzheimer’s disease

McGeer, P. L., & McGeer, E. G. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.988707 · Cited by 88 · see citing works

Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers

Soria, J., Massard, C. P., Magné, N., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.05.010 · Cited by 83 · see citing works

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial

Adenis, A., Blay, J., Bui-Nguyen, B., Bouché, O., Bertucci, F., Isambert, N., Bompas, E., Chaigneau, L., Dômont, J., Ray-Coquard, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu237 · Cited by 83 · see citing works

Mast cells: new targets for multiple sclerosis therapy?

Zappulla, J. P., Arock, M., Mars, L. T., & Liblau, R. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00250-3 · Cited by 78 · see citing works

Beta‐amyloid protein (25–35) disrupts hippocampal network activity: Role of Fyn‐kinase

Peña‐Ortega, F., Ordaz, B., Balleza‐Tapia, H., Bernal‐Pedraza, R., Márquez‐Ramos, A., Carmona‐Aparicio, L., & Giòrdano, M. (2009) · Hippocampus · doi:10.1002/hipo.20592 · Cited by 71 · see citing works

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study

Tebib, J. G., Xavier Mariette, A., Bourgeois, P., Flipo, R., Gaudin, P., Loët, X. L., Gineste, P., Guy, L., Mansfield, C. D., Moussy, A., et al. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2740 · Cited by 68 · see citing works

Differential Properties of Current Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors

Demetri, G. D. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.01.018 · Cited by 66 · see citing works

Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer

Mitry, E., Hammel, P. R., Deplanque, G., Mornex, F., Lévy, P., Seitz, J., Moussy, A., Kinet, J., Hermine, O., Rougier, P. R., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1299-8 · Cited by 59 · see citing works

Mast Cell Activation Causes Delayed Neurodegeneration in Mixed Hippocampal Cultures via the Nitric Oxide Pathway

Skaper, S. D., Facci, L., Romanello, S., & Leon, A. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66031157.x · Cited by 57 · see citing works

Amyloid β Peptides Trigger CD47-Dependent Mast Cell Secretory and Phagocytic Responses

Niederhoffer, N., Levy, R., Sick, É., André, P., Coupin, G., Lombard, Y., & Gies, J. (2009) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200902200224 · Cited by 46 · see citing works

Distribution of tryptase-containing mast cells and metallothionein reactive astrocytes in human brains with amyloid deposits

Maślińska, D., Laure‐Kamionowska, M., Maslinski, K. T., Gujski, M., & Maśliński, S. (2007) · Inflammation Research · doi:10.1007/s00011-006-0508-8 · Cited by 45 · see citing works

Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors

Nishida, T., Doi, T., & Naito, Y. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.937707 · Cited by 45 · see citing works

Mast Cells in Human Health and Disease

DeBruin, E., Gold, M., Lo, B. C., Snyder, K., Cait, A., Lasic, N., Lopez, M., McNagny, K. M., & Hughes, M. R. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1568-2_7 · Cited by 45 · see citing works

Targeting c-kit in the therapy of mast cell disorders: Current update

El‐Agamy, D. S. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.06.030 · Cited by 42 · see citing works

Involvement of Fyn tyrosine kinase in progression of cytokinesis of B lymphocyte progenitor.

Yasunaga, M., Yagi, T., Hanzawa, N., et al. (1996) · The Journal of Cell Biology · doi:10.1083/jcb.132.1.91 · Cited by 40 · see citing works

The majority of brain mast cells in B10.PL mice is present in the hippocampal formation

Hendrix, S., Warnke, K., Siebenhaar, F., et al. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.09.029 · Cited by 36 · see citing works

Imatinib Mesylate: An Innovation in Treatment of Autoimmune Diseases

Azizi, G., & Mirshafiey, A. (2013) · Recent Patents on Inflammation & Allergy Drug Discovery · doi:10.2174/1872213x113079990021 · Cited by 33 · see citing works

Discussion

Mattson, M. P. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01114-4 · Cited by 30 · see citing works

Tubulin-Independent Tau in Alzheimers Disease and Cancer: Implications for Disease Pathogenesis and Treatment

Souter, S. C., & Lee, G. S. (2010) · Current Alzheimer Research · doi:10.2174/156720510793611637 · Cited by 28 · see citing works

Impact of IL -9 and IL-33 in mast cells.

Sabatino, G., Nicoletti, M., Neri, G., et al. (2013) · PubMed · Cited by 24 · see citing works

Mast cell involvement in rheumatoid arthritis.

Kritas, S. K., Saggini, A., Varvara, G., et al. (2013) · PubMed · Cited by 23 · see citing works

Impact of Mast Cells on Multiple Sclerosis: Inhibitory Effect of Natalizumab

Kritas, S. K., Saggini, A., Cerulli, G. G., et al. (2014) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463201402700303 · Cited by 17 · see citing works

Dimerization of Kit‐ligand and efficient cell‐surface presentation requires a conserved Ser‐Gly‐Gly‐Tyr motif in its transmembrane domain

Paulhe, F., Wehrle‐Haller, M., Jacquier, M., et al. (2009) · The FASEB Journal · doi:10.1096/fj.09-129577 · Cited by 15 · see citing works

Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment

Folch, J., Petrov, D., Ettcheto, M., Abad, S., Sánchez-López, E., García, M. L., Olloquequi, J., Beas-Zarate, C., Auladell, C., & Camins, A. (2016) · Neural Plasticity · doi:10.1155/2016/8501693 · Cited by 270 · see citing works

From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology

Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179 · see citing works

Targeting Fyn Kinase in Alzheimer’s Disease

Nygaard, H. B. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.06.004 · Cited by 162 · see citing works

Therapeutic news in Alzheimer’s disease: Soon a disease-modifying therapy?

Villain, N. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.02.456 · Cited by 14 · see citing works

DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION

Mustafa, N. H., Kelesbayev, D., & Alibekova, Z. D. (2018) · The Journal of Economic Research & Business Administration · doi:10.26577/be-2018-2-2141

Susquehanna Chorale Spring Concert "Roots and Wings"

Hawkins, D. (2017)

Genentech taps Affimed’s antibodies

Cross, R. (2018) · C&EN Global Enterprise · doi:10.1021/cen-09635-buscon15

KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK

Sari, D. (2023) · Jurnal Komplikasi Anestesi · doi:10.22146/jka.v5i1.7322

Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria

Dib, A., Puig, L. B., Salvadori, D., et al. (1988) · Arquivos Brasileiros de Cardiologia